Managing multiple comorbidities is common in older adults. Thus, when a medication class, such as sodium-glucose cotransporter-2 (SGLT2) inhibitors, can potentially treat multiple conditions and prevent progression of chronic kidney disease, multiple guidelines must be followed when using these agents. The current article discusses risks and benefits of SGLT2 inhibitors, especially in the context of new evidence, and presents a case example. [Journal of Gerontological Nursing, 48(10), 7–13.]

中文翻译：

---

钠-葡萄糖协同转运蛋白 2 抑制剂：照顾老年人时的风险与回报

管理多种合并症在老年人中很常见。因此，当钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂等药物类别可以治疗多种疾病并预防慢性肾脏病的进展时，在使用这些药物时必须遵循多个指南。本文讨论了 SGLT2 抑制剂的风险和益处，特别是在新证据的背景下，并提供了一个案例。[老年护理杂志，48（10），7-13。]